Calreticulin as an Adjuvant In Vivo to Promote Dendritic Cell Maturation and Enhance Antigen-Specific T Lymphocyte Responses against Melanoma

Figure 4

Immunization with OVAp- or OVAp-CRT-pulsed DCs protects mice from challenge with B16-OVA tumor cells. (a) Mice were immunized with OVAp or OVAp-CRT on days 0, 7, and 14. Seven days after the final immunization, the mice were challenged by subcutaneous injection with control or OVA-transgenic B16 tumor cells (B16 and B16-OVA, respectively). Following B16-OVA or B16 cell inoculation, mouse survival was recorded. Tumor growth was monitored by measuring the tumor diameter every 3 days and recorded as the average tumor diameter. (b) DCs were stimulated with OVAp or OVAp-CRT. Mice were adoptively transferred with OVAp- or OVAp-CRT-pulsed DCs on days 0, 7, and 14. Seven days after the final immunization, the mice were challenged subcutaneously with B16-OVA tumor cells. Following B16-OVA tumor inoculation, mouse survival was recorded. Tumor growth was monitored by measuring the tumor diameter every 3 days and recorded as the average tumor diameter. mice per group. Data are representative of at least three independent experiments. . . .

(a)

(b)